Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: targetedmoab who wrote (204)	3/14/1998 4:26:00 PM
From: Barron Von Hymen	Read Replies (1) \| Respond to of 656

Does anyone know how far along Merck is on their COX inhibitors? These are small molecule drugs for pain that do not have the typical NSAID side effects such as gastric bleeding/ulceration. I wonder if thes COX-2 inhibitors might compete directly with Enbril as an anti-arthritic agent. I was also wondering what immunological side effects of Enbril might be also based on the fact that it is a biological macromolecule. Yours truly. BVH